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Nicholas A. Dewyer, Manu R. Varma, BS, Charles G. Pearce, BA, Gilbert R. Upchurch, Jr, MD,
Thomas W. Wakefield, MD, and Peter K. Henke, MD, Ann Arbor, Mich
Hypothesis: Deep venous thrombosis (DVT) confers vein wall injury associated with fibrosis and extracellular matrix
(ECM) turnover, likely mediated by matrix proteases. This study investigated the expression of proteases and collagen
involved in early vein wall remodeling.
Methods: In the mouse, DVT was produced by ligation of the infrarenal inferior vena cava (IVC) or sham operation, and
tissue was harvested at 4, 8, and 12 days. The vein wall tissue was processed for real-time reverse transcriptase-polymerase
chain reaction (6 to 8 per time point), Western immunoblotting (5 per time point), and gelatin zymography (5 per time
point). Analysis of variance was used for multiple comparisons, and a P < .05 was significant.
Results: Thrombus resolution was documented by a 38% decrease in the thrombosed IVC weight from day 4 to day 12
(P  .007). Total vein wall collagen increased over time, with a corresponding increase in procollagen I and III, and
expression peaked at 12 days (24-fold and 6.1-fold, respectively, P < .02). Matrix metalloproteinase-2 (MMP-2) gene
expression was 23-fold greater at 12 days after thrombus formation compared with sham or 4 days after thrombosis
(P < .05). Total MMP-2 activity was also significantly elevated at 12 days compared with sham (P < .05). MMP-9
expression was 19-fold and 27-fold higher at days 4 and 8, respectively, relative to sham (P < .05), with no difference in
activity. MMP-14 expression was twofold to 3.6-fold greater at day 12 compared with earlier time points and shams
(P < .001), but no differences in protein levels were found. Urokinase-type plasminogen activator (uPA) and
plasminogen activator inhibitor-1 (PAI-1) protein levels were not significantly different from sham over time; however,
the ratio of uPA to PAI-1 was decreased through 8 days.
Conclusions:Vein wall remodeling after DVT is similar to wound healing and is associated with increased procollagen gene
expression and total collagen. It is also associated with increased earlyMMP-9 expression, followed byMMP-2 expression
and activity after DVT resolution. (J Vasc Surg 2005;42:140-8.)
Clinical Relevance:Deep vein thrombosis is an often neglected problem that long term is associated with the postphlebitic
syndrome of limb swelling, pain, and often ulceration. The basic mechanisms of the vein wall damage that results have not
been delineated. The following study describes the vein wall matrix metalloproteinase gene and activity response induced
over time in the vein wall after DVT. Additionally, the corresponding collagen upregulation and proximate plasmin
system mediators are determined. With this knowledge, potential therapies to reduce vein wall injury directly might be
possible.Deep venous thrombosis (DVT) is an ongoing clinical
problem for hospitalized patients, affecting nearly 250,000
patients each year.1,2 In addition to the feared complication
of pulmonary embolism, DVT is associated with other
sequelae such as chronic venous insufficiency (CVI). A
young, active group of patients is typically affected by CVI,
resulting in significant morbidity (chronic venous stasis
ulcers, venous claudication) to an otherwise healthy popu-
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140lation.3,4 CVI has previously been associated with thick-
ened, fibrotic, and noncompliant vein walls and incompe-
tent valvular function.5
Further, it has been shown that DVT formation and
resolution are both strongly associated with inflamma-
tion.6,7 The subacute inflammatory reaction to DVT cre-
ates an environment with the release of proinflammatory
cytokines and leukocyte influx of neutrophils, followed
later by monocytes and macrophages, that promotes re-
modeling of the vessel wall. In this sense, DVT resolution is
akin to wound healing.
The matrix metalloproteinases (MMPs) are a family of
highly conserved, highly regulated enzymes that mediate
the remodeling of the extracellular matrix (ECM). MMPs
are regulated at the level of transcription, secretion, and
activation and are further regulated in vivo by the presence
of tissue inhibitors of metalloproteinases (TIMPs).8-10
MMPs are known to be active in wound healing and tissue
regeneration as well as in diseases that feature prominent
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disease.9,11 Further, it has been shown that MMP activity is
modulated in the presence of serine proteases, notably, plas-
min. This may be especially important in DVT resolution, as
plasmin is the prime mediator of fibrinolysis.12,13
Models of arterial vascular remodeling suggest both a
proteolytic and a fibroproliferative response. For example,
models of aneurysmal disease show elevated levels of matrix
metalloproteinases (especially MMP-2 and MMP-9) that
may contribute to a loss of wall elasticity and matrix
strength.14 Models of arterial occlusive disease demon-
strate increased numbers of activated vascular smooth mus-
cle cells and fibroblasts in atherosclerotic plaques and areas
of neointimal hyperplasia.15,16 Other studies have demon-
strated the accumulation of extracellular matrix proteins
(tropoelastin and fibronectin) and collagen deposition in
remodeling vessels, associated with localized activation of
MMPs.17 Additionally, some studies of arterial injury have
demonstrated an early accumulation of glycosaminoglycan
(GAG) after vessel injury, which has been postulated to
relate to the inflammatory response and cellular influx.18,19
Given the physiologic similarities between arteries and
veins, the aim of this study was to characterize the relation
of MMPs to DVT resolution, collagen metabolism, and
GAG metabolism in the vein wall.
MATERIALS AND METHODS
Mousemodel. Themodel of stasis-inducedDVT after
ligation of the inferior vena cava (IVC) has been described
previously.6,7,20,21 This experiment used 75 male BALB/
cmice weighing approximately 18 to 25 g and between 4 to
8 weeks of age. Only male mice were used to avoid the
potentially confounding effects of sex. The BALB/c strain
was chosen as it has provided the background for previous
experiments and has the availability of various genetic
knockouts. Animal care and handling was approved by the
University Committee on the Use and Care of Animals.
The mice were anesthetized with isoflurane inhala-
tional anesthesia and underwent laparotomy, with exposure
of the infrarenal IVC. The IVC was then dissected from the
adjacent section of aorta, and all visible side and back
branches distal to the renal veins and proximal to the iliac
bifurcation were ligated. The IVC was then ligated with a
single 8-0 Prolene suture (Ethicon, Somerville, NJ) imme-
diately distal to the renal veins. The sham group of mice
received the same preparation, along with dissection and
mobilization of the IVC, but a ligature was not placed on
the IVC nor were any side branches ligated.
The mice tolerated the procedure well and were recov-
ered in the laboratory before being returned to the animal
housing facility. All operative deaths occurred in the imme-
diate perioperative period and were related to anaesthetic
administration. No remote deaths secondary to infection
occurred, and the mice continued to feed well.
The mice were sacrificed at day 4, 8, or 12, and the
infrarenal IVC to the iliac bifurcation was harvested.
Thrombi were separated from the IVCs, and both were
measured for total length and weighed. The samples werethen immediately snap-frozen by immersion in liquid nitro-
gen and stored at –70°C for processing. One group of
samples was processed for mRNA extraction, one group
was processed for zymography and direct colorimetric as-
say, and one group was processed for Western blotting. For
these experiments, the IVC tissue was used for analysis.
Several samples from the group processed for zymography
were also sectioned for analysis by immunohistochemistry.
Measurement of thrombus and IVC weight.
Thrombus weights are a simple, but reliable, measure of
thrombus resolution.22 As this study was focused on the
vein wall, the weights of the thrombi, IVCs, and the com-
bined weights for each sample were measured. At the time
of harvest, thrombi were separated from the IVCs. The IVC
tissue was prepared for analysis in this study. The tissue was
prepared as described later for the following analyses.
Total glycosaminoglycan assay and total collagen
assay. The total GAG and total collagen content of the
vein wall were determined by using a commercially avail-
able direct colorimetric assay (Blyscan GAG Assay and
Sircol Collagen Assay, Biocolor Ltd, Belfast, Northern
Ireland). Samples underwent mechanical homogenization
and ultrasonic disruption in 500 L of lysis buffer, and the
assays were run according to the manufacturer’s instructions.
Values were standardized to the weight (mg) of IVC tissue
with an assay sensitivity of 1 g/mL. The collagen assay is a
quantitative assay in which Sirius red, an anionic dye, binds to
the side chains of amino acids found in collagens I to IV. In
theGAGassay, 1,9-dimethylmethylene blue dye is used under
conditions that produce a specific label for the sulfated poly-
saccharide component of proteoglycans and protein-free sul-
fated GAG chains, including chondroitin sulfates, dermatan
sulfates, keratin sulfates, and heparan sulfates.
Real-time reverse-transcriptase polymerase chain
reaction. Expression of each gene of interestwas determined
using a quantitative real-time polymerase chain reaction, as
described by Ginzinger.23 To extract mRNA, the tissue was
subjected to mechanical homogenization in TRIzol reagent
(Molecular Research Center, Inc, Cincinnati, Ohio) and
combined with chloroform. Samples were centrifuged, and
nucleic acids (RNA) were extracted from the aqueous layer.
The RNAwas subjected to reverse transcription to produce
cDNA.
Genes of interest and their respective sense and anti-
sense primers are listed in the Table. Primer sequences were
derived using Primer Premier Software (Premier Biosoft
Int, Palo Alto, Calif) and gene accession data available from
the National Institutes of Health LocusLink index to
GenBank. The expression for each gene was determined as
the relative expression, or cycle threshold (Ct), of the gene
of interest to the expression of -actin, a known, constitu-
tively expressed reference gene, by the formula:
Ct 2Ct -actinCt gene of interest
Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Activity of the gelatinases (MMP-2
and MMP-9, active and latent forms) was determined by
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previously described.24 Activity was visualized as light
staining bands on a dark background. Images were ana-
lyzed by densitometry performed with a FOTO/
Analyst CCD Camera (Fotodyne, Heartland, Wis) and
Gel-Pro Analyzer Software (v 3.1) (Media Cybernetics,
Silver Springs, Md) and normalized to the total amount of
protein present in each sample, as determined by the total
protein assay.
SDS-PAGE gelatin reverse zymography. The tissue
inhibitors of metalloproteinases (TIMPs) are the main
physiologic inhibitors of MMP activity in vivo.8 A per-
ceived increase in MMP activity can be related to increases
inMMP production or decreases in the production of these
natural MMP inhibitors. Activity of the TIMPs (active and
latent forms of TIMP-1, TIMP-2, and TIMP-3) was deter-
mined by zymography on 10% SDS polyacrylamide gels,
copolymerized with gelatin and human pro-MMP-2,
which degrades gelatin and is susceptible to inhibition by all
TIMPs, as previously described.24 Activity was visualized as
dark staining bands (areas of TIMP inhibition) on a light
background (area of MMP-2 activity). Images were ana-
lyzed by densitometry performed with a FOTO/Analyst
CCD Camera and Gel-Pro Analyzer Software (v 3) and
normalized to the total amount of protein present in each
sample as determined by the total protein assay.
Western immunoblot. Protein was extracted from
IVC samples by incubating IVC separated from thrombus
overnight in 1% SDS. Western blotting for urokinase-like
Table. Primers
Procollagen I sense
GCG AGT GCT GTG CTT TCT G
Procollagen I antisense
TCC CTC GAC TCC TAC ATC TTC
Procollagen III sense
GCC CAC AGC CTT CTA CAC
Procollagen III antisense
CCA GGG TCA CCA TTT CTC
MMP-9 sense
AGC ACA ACA GCT GAC TAC GAT AAG
MMP-9 antisense
GCG CTT CCG GCA CGC TGG AAT GAT CTA A
MMP-2 sense
GAT AAC CTG GAT GCT GTC G
MMP-2 antisense
CCA AAC TTC ACG CTC TTG
MMP-14 Sense
TTA CAA GTG ACA GGC AAG G
MMP-14 Antisense
AAC ACC ACA GCG AGG G
PAI-1 Sense
CCG ATG GGC TCG AGT ATG A
PAI-1 Antisense
TTG TCT GAT GAG TTC AGC ATC CA
-Actin sense
TTC TTT GCA GCT CCT TCG
-Actin antisense
TTC TGA CCC ATT CCC ACC
MMP, Matrix metalloproteinase; PAI, plasminogen activator inhibitor.plasminogen activator (uPA), plasminogen activatorinhibitor-1 (PAI-1), and MMP-14 was performed as previ-
ously described. (All buffers, gels, reaction chambers, and
membranes were from Bio-Rad, Hercules, Calif.)
Primary antibodies uPA (Santa Cruz Biotechnology,
Santa Cruz, Calif), PAI-1, andMMP-14 (BD Pharmingen,
San Diego, Calif) were diluted in Tris-buffered saline with
Tween-20 (T-TBS) to a dilution of 1:5,000 and applied to
the membranes for 1 hour at room temperature. After
washing, the corresponding secondary goat, rabbit, and
mouse antibodies (Calbiochem, San Diego, Calif) were
applied and incubated for 1 hour at room temperature. The
secondary antibodies were then also washed from the gel,
the labeled proteins were detected by the application of
enhanced chemiluminescence agents, and the membranes
were exposed to film for 10 to 45 seconds, depending on
the protein. (Detection reagents and film were from Amer-
sham Biosciences, Piscataway, NJ.) Images were detected
by using a FOTO/Analyst CCD Camera. Densitometry
was performed with Gel-Pro Analyzer Software (v 3) and
normalized to the total amount of protein present in each
sample, as determined by a commercially available total
protein assay (Pierce Biochemical, Rockford, Ill).
Statistical analysis. Descriptive statistics were col-
lected and data reported as mean  SEM. All data were
subjected to statistical analysis by one-way analysis of vari-
ance (normally distributed) or the Kruskal-Wallis (non-
normal distribution) for comparison between the various
time points represented, and when significance was found
(P 	 .05), t tests were used to compare thrombosed
samples with sham controls. Analysis was performed with
Fig 1. Thrombosed inferior vena cava (IVC) weight. The total
weight of the IVC and thrombus decreased from 4 days (earliest
time point with thrombus present) through 12 days, demonstrat-
ing thrombus resolution. The comparison here is between days 4,
8, and 12 of the experimental groups, as no thrombus was present
in animals that underwent sham operation (n 
 35). Data are
means  SEM, *P 	 .01 between day 4 and day 8, and between
day 8 and day 12.Sigma Stat (v 2.0), and graphic representations were cre-
icknes
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assigned as significant.
RESULTS
Total IVC collagen increases during thrombus
resolution. The sham IVCs were small, with a mean
weight of .376mg. The thrombosed IVCwere significantly
larger. The thrombosed IVC was heaviest, with a sixfold
increase at 4 days, and trended toward baseline over the
ensuing study period (Fig 1). Sham IVC samples demon-
strated minimal measurable collagen at the detection level
(1 g/mL) of the direct assay. However, vein wall collagen
increased significantly by 12 days after thrombosis com-
pared with shams (P	 .05). Conversely, an early increase in
the amount of GAGs present in vein walls was found after
Fig 2. Total collagen and glycosaminoglycan (GAG) c
increased significantly after thrombus formation, far abo
.015). b,Total GAGs, however, increased acutely but dec
12). As the duration of the thrombus exposure increase
collagen in the vessel wall demonstrated an increased thacute thrombus formation, followed by a decrease in vesselwall GAG content during thrombus resolution from day 4
to day 12 (n 
 4 to 5, P 	 .05). Additionally, an increase
in the amount of collagen staining in the vein wall was noted
in Brillmeyer’s trichrome sections of the thrombosed IVC
segments with the passage of time (Fig 2).
Procollagen I and III mRNA are upregulated dur-
ing thrombus resolution. In addition to results just
described, previous experimental work suggests collagen
content of the vein wall may increase acutely after
DVT.22 Expression of procollagen I mRNA, a subunit of
and precursor to type I collagen, increased 18-fold at day
8 and 24-fold at day 12 after DVT relative to sham (n 

6 to 8, P 	 .05). Procollagen III mRNA expression
increased sixfold at day 12 after DVT compared with
sham (n 
 6 to 8, P 	 .05). Day 4 levels for procollagen
nt (data are means  SEM). a, Total collagen content
e minimal amount detectable at baseline (n 
 5, *P 

d during the period of thrombus resolution (day 4 to day
m (c) 4 to (d) 12 days, Brillmeyer’s trichrome stain for
s (arrows) of the vein wall (n 
 5) (125).onte
ve th
rease
d froI and procollagen III mRNA were increased above base-
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the sham animals (Fig 3).
MMP-9 expression and activity are increased early
in the IVC during DVT resolution. During the course
of DVT resolution, MMP-9 mRNA increased by 20-fold at
day 4 and 28-fold at day 8 relative to sham (n
 6 to 8, P	
.05). By day 12, the level of MMP-9 mRNA was no
different from shams. MMP-9 activity by zymographic
assessment was increased relative to sham controls. Most of
this increase occurred early, as there was a fivefold increase
in total activity between sham and day 4 (n
 5, P
 .007).
Total MMP-9 activity remained increased through day 12,
although there was a slight (insignificant) decline in activity
between day 4 and day 12 (Fig 4).
Fig 3. Procollagen I and III expression (data are means SEM).
a, Procollagen I expression was increased 18-fold by day 8 and
24-fold by day 12 after deep vein thrombosis, both relative to sham
(n 
 6 to 8; *P 
 .06). b, Procollagen III expression increased
sixfold by day 12 (n 
 6 to 8, *P 
 .017).MMP-2 expression and activity are increased laterin the IVC during DVT resolution. MMP-2 mRNA
expression increased significantly during thrombus resolu-
tion and peaked at day 12. There was a 10-fold increase in
expression at day 12 relative to sham tissue (n
 6 to 8, P	
.05). Additionally, total MMP-2 activity (the activity of
both pro- and active forms of the protease) increased
during thrombus resolution. Total activity was 2.8-fold
greater at day 12 than in sham tissue (n 
 5,
P 	 .05) A 1.5-fold increase was present by day 8, but this
did not reach statistical significance. Additionally, the
amount of MMP-2 detectable as the active form of the
enzyme was also increased by 2.6-fold at day 12 (n 
 5,
P	 .03). In a similar result to the total amount of MMP-2
activity, there was a 1.6-fold increase by day 8, but again,
this did not reach statistical significance (Fig 5).
MMP-14 is a membrane-type (membrane associated)
metalloproteinase that is known to be a proximal activator
of other metalloproteinases, notably MMP-2.8,25 In the
present study, MMP-14 mRNA expression was increased by
6.4-fold on day 12 relative to the shamgroup (n
 6 to 8,P	
.05). Despite the increased mRNA expression of MMP-14,
however, no statistically significant change in the protein level
was detectable by Western immunoblot by day 12.
No change in IVCTIMP levels occurred duringDVT
resolution. Reverse zymography for TIMP inhibition of
MMP activity demonstrated no statistically significant al-
terations in TIMP-1 (20.6 kDa TIMP) levels at any time
point (n 
 4 to 5, P 
 .48; data not shown).
Protein levels of uPA and PAI-1 in the IVC trend
in opposite directions during DVT resolution. The
MMPs are known to be affected by serine proteases,
notably, the plasmin system.8,26 Therefore, we sought to
establish variations in the plasminogen-plasmin axis—the
process andmediators involved in the activation of plasmin-
ogen to form plasmin—that might play a role, directly or
indirectly, in the activation of MMPs. PAI-1 is the primary
native inhibitor of plasmin activation. By Western immu-
noblotting, the level of PAI-1 protein trended upward and
peaked at day 8 (sham optical density [OD], 0.212/mg
protein vs 8 day OD, 0.328/mg protein), whereas uPA
declined from sham controls to day 12, with most of the
decrease occurring by day 8 (sham OD, 2.1/mg protein vs
8 day OD, 0.81/mg protein).
To reflect the relative balance of uPA (profibrinolytic)
to PAI-1 (antifibrinolytic), we assessed the ratio of these
antigen levels.27,28 Although the change in the absolute
amounts of uPA and PAI-1 did not change significantly,
there was a significant change in the ratio of these proteins
in the IVC. The ratio of uPA to PAI-1 was 5.7 times higher
in the sham group than at the 8-day time point, a drop of
83% (P 
 .044) (Fig 6).
DISCUSSION
DVT resolution is known to be an inflammatory process,
with clinical sequela that includes chronic venous insuffi-
ciency, marked by thickened, noncompliant vein walls and
incompetent valves. Previous studies have suggested a role for
the thrombus in directing the inflammatory reaction that
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 1 Deatrick et al 145Fig 4. Matrix metalloproteinase-9 (MMP-9) expression and activity (data are means  SEM). a, Expression of
MMP-9mRNAwas increased 19.5-fold at 4 days and 27.5-fold at 8 days, both relative to sham (n
 6 to 8; *P
 .004).
b, MMP-9 activity by zymogram peaked at day 4 (5-fold greater) compared with shams (n 
 4 to 5, *P 
 .011). c,
Representative composite zymogram showing activity as a bright band on a dark background. There are four columns,
each containing three separate samples from separate animals.Fig 5. Matrix metalloproteinase-2 (MMP-2) expression and activity (data are means  SEM). a,MMP-2 expression
was 10-fold greater at day 12 than in shams (n
 6-8; *P	 .001). b,MMP-2 activity peaked at day 12, 2.8-fold greater
than in shams (n 
 4 to 5; *P 
 .011) c, Representative composite zymogram showing activities. There are four
columns, each containing three separate samples from separate animals.
arate
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nidus of inflammation temporally with changes in the vessel
wall itself. We hypothesized that the inflammatory reaction
that allows resolution of the thrombuswould be related to the
inflammation in the vein wall, as the mediators secreted at the
thrombus-vessel interface should affect not only the thrombus
but also the adjacent vessel wall.
The interrelation between thrombosis and inflamma-
tion has been long demonstrated.5-7,22 Thrombus resolu-
Fig 6. Urokinase-like plasminogen activator (uPA) and
SEM). a,The ratio of uPA to PAI-1 protein levels diminis
b, and c, The attached blots are representative of the rel
columns, each containing two separate samples from seption is an active process of inflammation, with early neutro-phil influx followed by the eventual replacement with cells
of the monocyte-macrophage lineage.6,22 This contributes
to the secretion of a number of proinflammatory cytokines
that may direct extracellular matrix turnover.
Prior experimental study has suggested that a late fi-
brotic response, similar to a healing wound, occurs in vein
walls after the development of a DVT.5 This involves the
progression of the normally thin and compliant vein wall to
a relatively thick and fibrotic state, with the deposition and
inogen activator inhibitor-1 (PAI-1) (data are means
om sham controls through day 8 (n
 4 to 5; *P
 .044)
intensity of the staining for each protein. There are four
animals.plasm
hed fr
ativeaccumulation of collagen and the loss of normal vessel
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 1 Deatrick et al 147ECM. Some of these studies have indicated a role for
MMPs in the resolution of the thrombus, but patterns of
expression for these proteinases, as well as the proximal
effectors in the MMP system, have not been well character-
ized in the vein wall.22
This study demonstrates that MMP gene expression
and activity is differentially induced in the vein wall after the
formation of a DVT; that is, whereas multiple MMPs may
be activated during the process of DVT resolution, the
most significant long-term alterations in function occur in
MMP-2. Put alternatively, although changes occur in the
activity of other MMPs such as MMP-7 andMMP-9, these
changes lose significance 4 days, and MMP-2 activation
at a later time point seems to suggest that it is the gelatinase
with the most significant impact on chronic remodeling of
the ECM. Furthermore, this correlates with increased pro-
collagen gene expression and total collagen levels.
Neutrophils are known to be the primary source of both
secreted and membrane-associated MMP-9, which has been
shown to play a role in cell invasion and migration through
normal matrix.29 Consistent with this notion is the observed
early increase in IVC MMP-9 activity. Persistent elevation of
MMP-9 gene expression and activity suggests cells other than
neutrophils may later modulate MMP-9 production as the
thrombus resolves. It is likely this protease is involved with
early ECM turnover, probably released from the infiltrating
neutrophils that occurs after DVT.5,20
Though MMP-9 was prominent early, MMP-2 had
greater and more persistent elevation of gene expression
and activity in the vessel wall at later time points. MMP-2 is
expressed by smooth muscle cells and fibroblasts and is
activated during the vessel response to injury.15,30,31 This
protease degrades elastin and collagens, and its relatively
late upregulation suggests that it may be most important in
the remodeling of the ECM deposited as part of the scar
matrix rather than in the degradation of the normal ECM
or in the actual lysis of the thrombus itself. Interestingly,
MT-1 MMP (MMP-14), known to be an activator of
MMP-2, showed an increase in amount early after DVT.
Whether this is integrally related to MMP-2 activation has
not been evaluated in the current study.8,25 Thus, activa-
tion of MMP-2 in the perithrombus vein wall may or may
not be dependent on increased production of MMP-14.
Venous thrombolysis in vivo is mediated primarily by
activation of the plasminogen-plasmin system.32 Plasmin, a
serine protease, is a proximal activator of MMP activity.26 It
is perhaps not surprising that in a resolving thrombus,
MMP activation may occur as the result of activation by the
plasmin system, and this activity may be present in the vein
wall as well. Additionally, PAI-1 is known to be involved in
interleukin-1–mediated matrix remodeling by macro-
phages.33-35 Given that uPA is a central activator of fibri-
nolysis, the observed decrease in vein wall uPA may repre-
sent its consumption as it activates plasminogen to plasmin
during the acute phase of thrombolysis and possibly by
downregulation with increases in MMP-2 and -9. The
changing ratio of uPA and PAI-1 demonstrates an alter-
ation in the normal profibrinolytic to antifibrinolytic stateof the vessel. However, we acknowledge and caution that
the ratio comparison is subject to error propagation of the
numerator and denominator. The definitive method to
quantify this would be a direct activity assay, which has so
far proved elusive in our model system.
In other studies, loss of uPA activity confers a relatively
antifibrinolytic state, with increased fibrin deposition.28,36
Interestingly, the decrease of this ratio in this model dem-
onstrates a shift away from a relatively profibrinolytic state
(uPA-rich) to a relatively antifibrinolytic state (PAI-1-rich).
Normal endothelium maintains a relatively profibrinolytic
state that prevents the formation of pathologic thrombosis
and aids in the clearance of fibrin products after normal
hemostasis.36,37 Thus, we speculate that the DVT does
damage to the vein wall endothelium, which may act to
promote continuing thrombus deposition that is only ab-
rogated once the vessel has re-endothelialized.
These data support the belief that normal vein wall
matrix is replaced with contents similar to those that are
found in a healing wound.38 There was a marked increase in
the amount of collagen present in the IVC segments late in
the resolution process. Consistent with the increase in total
collagen, an increase was found in procollagen I and pro-
collagen III, which are both known to be a part of wound
granulation tissue.38,39 The profibrotic mediator trans-
forming growth factor- is released from thrombus during
thrombolysis40 and suggests that the thrombus itself may
direct the vein wall response. Indeed, this has been shown
in the rat model of DVT (unpublished data by Henke).
Conversely, there was an acute peak in the amount of
GAGs, followed by a steep decrease from day 4 through day
12. This could represent an acute increase in the presence of
heparan or the release of chondroitin sulfate in response to the
immediate inflammation associated with thrombosis, fol-
lowed by degradation in the process of matrix replacement.41
Another possible explanation for the acute increase in the
presence of GAGs in the sample relates to the immediate
response to tissue injury. Models of arterial injury have dem-
onstrated an acute increase in GAG components of the ECM
after damage to the vessel.18,19 In these systems, it has been
suggested that these matrix components are secreted by
smooth muscle cells and fibroblasts in the vascular media and
facilitate the influx of inflammatory cells. A similar phenome-
non may be occurring that allows the development of the
thrombus-associated inflammation. In these models, there is
an acute peak in GAG, allowing for the development of acute
inflammation, followed by a decline over time. Although this
occurs in a long-term time scale, such a phenomenon could
account for our results. Alternatively, heparan sulfate proteo-
glycans may be released and consumed through activation of
the fibrinolytic system during the process of thrombus resolu-
tion.
The current study does not differentiate the roles of
influxing leukocytes from the stimulated resident vein wall
cellular production of theMMPs. The role of the thrombus
itself (and the timing of thrombus duration as a mechanism
in directing MMP activity) is not defined here but is the
subject of ongoing studies. Furthermore, whether these
JOURNAL OF VASCULAR SURGERY
July 2005148 Deatrick et alproteases can be targeted selectively to decrease the de-
structive injury response is attractive but premature.
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